leisure time -WSS

leisure time

author：knowledge 2025-08-26 02:49:15 - browse：2

Pfizer plans to exit a major biotechnology industry trade association. Cindy Ord/Getty Images for Pfizer/BioNTech

WASHINGTON — Pfizer has decided to leave the Biotechnology Innovation Organization, according to two sources familiar with the planning.

The departure is a blow to BIO, which represents members ranging from small biotech startups to massive pharmaceutical companies. The group on Tuesday announced its new CEO, rare disease advocate and biotech executive John Crowley.

“The economic situation for the industry is difficult indeed and we of course are disappointed that any company would be forced to take a break from its BIO membership. We certainly hope that when economic conditions improve, we can welcome those companies back and welcome new members to join us as well, but it in no way affects our mission of protecting patients and medical innovation in the United States,” said BIO’s Chief Public Affairs and Marketing Officer Rich Masters. Masters said he wouldn’t comment on the status of any particular member.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： One Duchenne patient's bittersweet hope for new treatment

WSS

Beam Therapeutics to lay off 20% of its staff, re

Inflation cooled significantly in June, bringing price hikes close to normal levels

Giant panda gives birth to squirming, squealing healthy twin girls at South Korean theme park

2023 STAT Wunderkinds: get to know the winners

Beam Therapeutics to lay off 20% of its staff, re

The explosion of genetic testing requires a new approach

focus

leisure time

hotspot

The high cost of giving birth even with insurance

Va. Republicans encourage early voting, a target of Trump's, ahead of fall elections

The cancer drug shortage isn’t new — and neither are the solutions

Va. Republicans encourage early voting, a target of Trump's, ahead of fall elections

The high cost of giving birth even with insurance

How climate

BioMarin wins approval for gene therapy to treat hemophilia A

NIH confirmation hearing shows politicization of research

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Eli Lilly expects to double planned employment in Boston center

focus

UnitedHealth’s board chair also owns a personal investment firm

Grail's uphill battle for Medicare to cover its cancer screening test

NIH confirmation hearing shows politicization of research

Why health workers in Gaza are injured or die at high rates

Pharmacists can make shortage drugs, but at what cost?

Sickle cell gene therapy cures need to be accessible in Africa

explore

knowledge

leisure time

focus